Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: Relationship to tumor hypoxia

Cancer Research

Volumn 57, Issue 14, 1997, Pages 2922-2928

  Siim, Bronwyn G ^a,b   Menke, Douglas R ^a   Dorie, Mary Jo ^a   Martin Brown, J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; TIRAPAZAMINE;

ANIMAL MODEL; ARTICLE; CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; CELL HYPOXIA; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; ENZYME ACTIVITY; FIBROSARCOMA; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG CARCINOMA; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DNA; DNA DAMAGE; ETANIDAZOLE; HUMANS; HYDROCARBONS, FLUORINATED; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 0030871773     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67: 1163-1170, 1993.
2. Wang, J., Biedermann, K. A., and Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res., 52: 4473-4477, 1992.
3. Elwell, J. H., Siim, B. G., Evans, J. W., and Brown, J. M. Adaptation of human cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity., Biochem. Pharmacol., in press, 1997.
4. Herscher, L. L., Krishna, M. C., Cook, J. A., Coleman, C. N., Biaglow, J. E., Tuttle, S. W., Gonzalez, F. J., and Mitchell, J. B. Protection against SR 4233 (tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. Int. J. Radiat. Oncol. Biol. Phys., 30: 879-885, 1994.
5. Silva, J. M., and O'Brien, P. J. Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions. Br. J. Cancer, 68: 484-491, 1993.
6. Wilson, W. R. Tumour hypoxia: challenges for cancer chemotherapy. In: M. J. Waring and B. A. J. Ponder (eds.), The Search for New Anticancer Drugs, Cancer Biology and Medicine, Vol. 3, pp. 87-131. Lancaster: Kluwer Academic Publishers, 1992.
7. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumors. Cancer Res., 48: 775-778, 1988.
8. Brown, J. M., and Siim, B. G. Hypoxia-specific cytotoxins in cancer therapy. Semin. Radiat. Oncol., 6: 22-36, 1996.
9. Moulder, J. E., and Rockwell, S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev., 5: 313-341, 1987.
10. Rockwell, S., and Moulder, J. E. Hypoxic fractions of human tumors xenografted into mice: a review. Int. J. Radiat. Oncol. Biol. Phys., 19: 197-202, 1990.
11. Vaupel, P. W., and Hockel., M. Oxygenation status of human tumors: a reappraisal using computerized pO2 histography. In: P. W. Vaupel, D. K. Kelleher, and M. Gunderoth (eds.), Tumor Oxygenation, pp. 219-232. Stuttgart: Gustav Fischer Verlag, 1995.
12. Nordsmark, M., Overgaard, M., and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 41: 31-40, 1996.
13. Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., and Hartz, W. H. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 14: 831-838, 1988.
14. Fyles, A., Milosevic, M., Kavanagh, M-C., Pintilie, M., Sun, A., Chapman, W., Levin, W., Manchul, L., Keane, T. J., and Hill, R. Hypoxia measured with a polarographic electrode correlates with radiation response in cervix cancer. Radiother. Oncol., in press, 1997.
15. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol., 26: 45-50, 1993.
16. Kolstad, P. Vascularization, oxygen tension, and radiocurability in cancer of the cervix. Copenhagen: Scandinavian University Books, 1963.
17. Brown, J. M., and Koong, A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J. Natl. Cancer Inst., 83: 178-185, 1991.
18. Brown, J. M., and Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50: 7745-7749, 1990.
19. Stone, H. B., Brown, J. M., Phillips, T. L., and Sutherland, R. M. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Radiat. Res., 136: 422-434, 1993.
20. Siim, B. G., van Zijl, P. L., and Brown, J. M. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity toward hypoxic tumour cells in vitro. Br. J. Cancer, 73: 952-960, 1996.
21. Olive, P. L., Vikse, C. M., and Banath, J. P. Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice. Cancer Res., 56: 4460-4463, 1996.
22. Hirst, D. G., Brown, J. M., and Hazlehurst, J. L. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res., 43: 1961-1965, 1983.
23. Rockwell, S. C., Kallman, R. F., and Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue culture-adapted derivative. J. Natl. Cancer Inst., 49: 735-749, 1972.
24. Twentyman, P. R., Brown, J. M., Gray, J. W., Franko, A. J., Scoles, M. A., and Kallman, R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J. Natl. Cancer Inst., 64: 595-604, 1980.
25. Koch, C. J., Evans, S. M., and Lord, E. M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-l-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs. bound radioactivity. Br. J. Cancer, 72: 865-870, 1995.
26. Horsman, M. R., Brown, J. M., Hirst, V. K., Lemmon, M. J., Wood, P. J., Dunphy, E. P., and Overgaard, J. Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int. J. Radiat. Oncol. Biol. Phys., 15: 685-690, 1988.
27. Horsman, M. R., Chaplin, D. J., and Brown, J. M. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res., 109: 479-489, 1987.
28. Siemann, D. W., Horsman, M. R., and Chaplin, D. J. The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother. Oncol., 31: 117-122, 1994.
29. Olive, P. L., Wlodek, D., Durand, R. E., and Banath, J. P. Factors influencing DNA migration from individual cells subjected to gel electrophoresis. Exp. Cell Res., 198: 259-267, 1992.
30. Olive, P. L., and Durand, R. E. Detection of hypoxic cells in a murine tumor with the use of the Comet assay. J. Natl. Cancer Inst., 84: 707-711, 1992.
31. Olive, P. L., Banath, J. P., and Durand, R. E. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat. Res., 122: 86-94, 1990.
32. Evans, S. M., Joiner, B. J., Jenkins, W. T., Laughlin, K. M., Lord, E. M., and Koch, C. J. Identification of hypoxia in cells and tissues of epigastric 9L rat tumours using EF5. Br. J. Cancer, 72: 875-882, 1995.
33. Olive, P. L. Distribution, oxygenation, and clonogenicity of macrophages in a murine tumor. Cancer Commun., 1: 93-100, 1989.
34. Collard, J., Matthew, A. M., Double, J. A., and Bibby, M. C. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br. J. Cancer, 71: 1199-1203, 1995.
35. Hejmadi, M. V., McKeown, S. R., Friery, O. P., McIntyre, I. A., Patterson, L. H., and Hirst, D. G. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br. J. Cancer, 73: 499-505, 1996.
36. Kjellen, E., Joiner, M. C., Collier, J. M., Johns, H., and Rojas, A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol., 22: 81-91, 1991.
37. Chaplin, D. J., Horsman, M. R., and Aoki, D. Nicotinamide, fluosol DA, and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br. J. Cancer, 63: 109-113, 1991.
38. Dorie, M. J., Menke, D., and Brown, J. M. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int. J. Radiat. Oncol. Biol. Phys., 28: 145-150, 1994.
39. Sasai, K., and Brown, J. M. Discrepancies between measured changes of radiobiological hypoxic fraction and oxygen tension monitoring using two assay systems. Int. J. Radiat. Oncol. Biol. Phys., 30: 355-361, 1994.
40. Koch, C. J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res., 53: 3992-3997, 1993.